Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

NCT03907488 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03907488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03907488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 29, 2019
Completion date
March 28, 2027
Enrollment
994 (actual)
Sites
728

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage iii hodgkin lymphoma, ann arbor stage iii lymphocyte-depleted classic hodgkin lymphoma, ann arbor stage iii mixed cellularity classic hodgkin lymphoma, ann arbor stage iii nodular sclerosis classic hodgkin lymphoma, ann arbor stage iv hodgkin lymphoma, ann arbor stage iv lymphocyte-depleted classic hodgkin lymphoma, ann arbor stage iv mixed cellularity classic hodgkin lymphoma, ann arbor stage iv nodular sclerosis classic hodgkin lymphoma, classic hodgkin lymphoma, lymphocyte-rich classic hodgkin lymphoma